Updated on 7 October 2013
Dr Gruberg said if the US Food and Drug Administration approves the new stent, patients will have an option that frees them from having a lifelong implant. The device is implanted via a balloon-tipped catheter, as are conventional stents. The catheter is threaded through a blood vessel in the groin to reach the blockage. When the balloon is inflated, the stent expands and is locked in place.
Stony Brook University is one of four sites on Long Island and five in New York City participating in the nationwide ABSORB III clinical trial. The device was developed by California-based Abbott Vascular, a division of pharmaceutical giant Abbott Laboratories, which is based in Illinois.
The study is a randomized, controlled, double-blind trial, which means some patients will receive a conventional stent, while others are implanted with a dissolving one. It's expected that more than 2,000 patients will be tested.